Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
Ventyx Biosciences (NASDAQ: VTYX), a clinical-stage biopharmaceutical company developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. Company executives will engage in a fireside chat on Thursday, June 5, 2025, from 12:50-1:20 PM ET in New York. The presentation will be accessible via webcast on the company's website at www.ventyxbio.com, with a replay available for 90 days following the event.
Ventyx Biosciences (NASDAQ: VTYX), un'azienda biofarmaceutica in fase clinica che sviluppa terapie orali per malattie autoimmuni, infiammatorie e neurodegenerative, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. I dirigenti dell'azienda parteciperanno a una conversazione informale il giovedì 5 giugno 2025, dalle 12:50 alle 13:20 ET a New York. La presentazione sarà disponibile in webcast sul sito web dell'azienda all'indirizzo www.ventyxbio.com, con una replica accessibile per 90 giorni dopo l'evento.
Ventyx Biosciences (NASDAQ: VTYX), una compañía biofarmacéutica en etapa clínica que desarrolla terapias orales para enfermedades autoinmunes, inflamatorias y neurodegenerativas, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. Los ejecutivos de la empresa participarán en una charla informal el jueves 5 de junio de 2025, de 12:50 a 13:20 ET en Nueva York. La presentación estará disponible a través de webcast en el sitio web de la empresa en www.ventyxbio.com, con una repetición accesible por 90 días después del evento.
Ventyx Biosciences (NASDAQ: VTYX)는 자가면역, 염증 및 신경퇴행성 질환을 위한 경구 치료제를 개발하는 임상 단계 생명공학 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여할 예정임을 발표했습니다. 회사 임원들은 2025년 6월 5일 목요일, 동부시간 오후 12시 50분부터 1시 20분까지 뉴욕에서 진행되는 비공식 대화에 참여할 예정입니다. 발표는 회사 웹사이트 www.ventyxbio.com에서 웹캐스트로 시청할 수 있으며, 행사 후 90일 동안 다시보기 서비스가 제공됩니다.
Ventyx Biosciences (NASDAQ : VTYX), une société biopharmaceutique en phase clinique développant des thérapies orales pour les maladies auto-immunes, inflammatoires et neurodégénératives, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Les dirigeants de l'entreprise participeront à une discussion informelle le jeudi 5 juin 2025, de 12h50 à 13h20 ET à New York. La présentation sera accessible en webcast sur le site internet de l'entreprise à l'adresse www.ventyxbio.com, avec un replay disponible pendant 90 jours après l'événement.
Ventyx Biosciences (NASDAQ: VTYX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das orale Therapien für Autoimmun-, Entzündungs- und neurodegenerative Erkrankungen entwickelt, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Die Unternehmensleitung wird am Donnerstag, den 5. Juni 2025, von 12:50 bis 13:20 Uhr ET in New York an einem informellen Gespräch teilnehmen. Die Präsentation wird per Webcast auf der Unternehmenswebsite www.ventyxbio.com verfügbar sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung abrufbar ist.
- None.
- None.
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference.
- Event: Jefferies Global Healthcare Conference, New York
Fireside Chat
Date: Thursday, June 5, 2025
Time: 12:50-1:20 PM ET
A webcast of the event will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for ninety days.
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials.
Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases. Our inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor.
For more information on Ventyx, please visit our website at https://ventyxbio.com.
Investor Relations Contact:
Joyce Allaire
Managing Director
LifeSci Advisors
IR@ventyxbio.com
FAQ
When is Ventyx Biosciences (VTYX) presenting at the Jefferies Healthcare Conference 2025?
Where can I watch Ventyx Biosciences (VTYX) Jefferies conference presentation?
What type of diseases does Ventyx Biosciences (VTYX) focus on?
What is the format of Ventyx Biosciences' (VTYX) presentation at the Jefferies conference?
